{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=HER2-positive&page=2", "query": { "condition": "HER2-positive", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=HER2-positive&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-06-10T10:19:16.593Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01275677", "title": "Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HER2/Neu Positive", "Progesterone Receptor Positive", "Recurrent Breast Carcinoma", "Stage IA Breast Cancer AJCC v7", "Stage IB Breast Cancer AJCC v7", "Stage IIA Breast Cancer AJCC v6 and v7", "Stage IIB Breast Cancer AJCC v6 and v7", "Stage IIIA Breast Cancer AJCC v7", "Stage IIIC Breast Cancer AJCC v7" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Trastuzumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "OTHER", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 3270, "start_date": "2011-02-08", "completion_date": "2025-06-02", "has_results": true, "last_update_posted_date": "2025-07-14", "last_synced_at": "2026-06-10T10:19:16.593Z", "location_count": 1259, "location_summary": "Anniston, Alabama • Mobile, Alabama • Anchorage, Alaska + 797 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT01275677" }, { "nct_id": "NCT05035836", "title": "A Phase 2 Single-Arm Open-Label Pilot Trial Evaluating Zanidatamab (ZW25) in Patients With Early Stage HER2/Neu Positive (HER2+) Breast Cancer (BC)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer", "HER2-positive" ], "interventions": [ { "name": "Zanidatamab", "type": "DRUG" }, { "name": "Letrozole", "type": "DRUG" }, { "name": "Tamoxifen", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 20, "start_date": "2021-11-16", "completion_date": "2028-12-29", "has_results": false, "last_update_posted_date": "2026-06-05", "last_synced_at": "2026-06-10T10:19:16.593Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05035836" }, { "nct_id": "NCT01576666", "title": "Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Dose Escalation", "Safety", "Preliminary Efficacy", "Advanced Solid Tumors", "Metastatic Breast Cancer", "Advanced Pancreatic Adenocarcinoma", "Metastatic Colorectal Cancer", "Recurrent Glioblastoma Multiforme", "Gastric Cancer", "Gastroesophageal Junction Cancer", "Triple Negative Metastatic Breast Cancer", "Hormone Receptor Positive (ER+/PR+, and Her2-) Metastatic Breast Cancer" ], "interventions": [ { "name": "LDE225", "type": "DRUG" }, { "name": "BKM120", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 120, "start_date": "2012-07", "completion_date": "2015-04", "has_results": false, "last_update_posted_date": "2020-12-19", "last_synced_at": "2026-06-10T10:19:16.593Z", "location_count": 13, "location_summary": "Los Angeles, California • San Francisco, California • Tampa, Florida + 9 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT01576666" }, { "nct_id": "NCT07102381", "title": "A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HER2-positive Breast Cancer", "Breast Cancer" ], "interventions": [ { "name": "Zanidatamab", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" }, { "name": "Pertuzumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Jazz Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 125, "start_date": "2025-09-24", "completion_date": "2030-08-01", "has_results": false, "last_update_posted_date": "2026-04-29", "last_synced_at": "2026-06-10T10:19:16.593Z", "location_count": 22, "location_summary": "Long Beach, California • Denver, Colorado • Lakeland, Florida + 18 more", "locations": [ { "city": "Long Beach", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Lakeland", "state": "Florida" }, { "city": "Ames", "state": "Iowa" }, { "city": "Shreveport", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT07102381" }, { "nct_id": "NCT04739761", "title": "A Study of T-DXd in Participants With or Without Brain Metastasis Who Have Previously Treated Advanced or Metastatic HER2 Positive Breast Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Trastuzumab Deruxtecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 506, "start_date": "2021-06-22", "completion_date": "2027-05-26", "has_results": true, "last_update_posted_date": "2026-05-12", "last_synced_at": "2026-06-10T10:19:16.593Z", "location_count": 2, "location_summary": "Boston, Massachusetts • Durham, North Carolina", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT04739761" }, { "nct_id": "NCT04395508", "title": "An Expanded Access Study to Provide at Home Subcutaneous Administration of Pertuzumab and Trastuzumab Fixed-Dose Combination (PH FDC SC) for Patients With HER2-Positive Breast Cancer During the COVID-19 Pandemic", "overall_status": "APPROVED_FOR_MARKETING", "study_type": "EXPANDED_ACCESS", "phases": [], "conditions": [ "HER2-positive Breast Cancer" ], "interventions": [ { "name": "Pertuzumab and Trastuzumab Fixed-Dose Combination for Subcutaneous Administration (PH FDC SC)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2022-07-05", "last_synced_at": "2026-06-10T10:19:16.593Z", "location_count": 12, "location_summary": "Beverly Hills, California • San Francisco, California • Stanford, California + 9 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04395508" }, { "nct_id": "NCT03125928", "title": "Clinical Trial of Atezolizumab With Paclitaxel, Trastuzumab, and Pertuzumab in Patients With Metastatic HER-2 Positive Breast Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HER2-positive Breast Cancer" ], "interventions": [ { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" }, { "name": "Pertuzumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Fox Chase Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 16, "start_date": "2017-06-13", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2026-05-22", "last_synced_at": "2026-06-10T10:19:16.593Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03125928" }, { "nct_id": "NCT00696072", "title": "Randomized Phase II Trial of Letrozole With or Without Dasatinib as First and Second-line Treatment for Hormone Receptor-positive, HER2-negative Post-menopausal Breast Cancer That is Unresectable, Locally Recurrent or Metastatic", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Breast Cancer" ], "interventions": [ { "name": "Dasatinib", "type": "DRUG" }, { "name": "Letrozole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 120, "start_date": "2008-08", "completion_date": "2014-06", "has_results": true, "last_update_posted_date": "2016-06-13", "last_synced_at": "2026-06-10T10:19:16.593Z", "location_count": 27, "location_summary": "Sedona, Arizona • Tucson, Arizona • Denver, Colorado + 22 more", "locations": [ { "city": "Sedona", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Denver", "state": "Colorado" }, { "city": "Hudson", "state": "Florida" }, { "city": "Carmel", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT00696072" }, { "nct_id": "NCT04622319", "title": "A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HER2-Positive Primary Breast Cancer", "Residual Invasive Breast Cancer" ], "interventions": [ { "name": "DS-8201a", "type": "DRUG" }, { "name": "T-DM1", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daiichi Sankyo", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1600, "start_date": "2020-12-04", "completion_date": "2028-06-20", "has_results": false, "last_update_posted_date": "2026-05-15", "last_synced_at": "2026-06-10T10:19:16.593Z", "location_count": 126, "location_summary": "Anaheim, California • Baldwin Park, California • Bellflower, California + 94 more", "locations": [ { "city": "Anaheim", "state": "California" }, { "city": "Anaheim", "state": "California" }, { "city": "Baldwin Park", "state": "California" }, { "city": "Bellflower", "state": "California" }, { "city": "Fontana", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04622319" }, { "nct_id": "NCT05954143", "title": "Trial of BDC-1001 +/- Pertuzumab in Subjects With HER2-Positive Metastatic Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Breast Cancer", "HER2-positive Breast Cancer" ], "interventions": [ { "name": "BDC-1001", "type": "DRUG" }, { "name": "Pertuzumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bolt Biotherapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 11, "start_date": "2023-11-30", "completion_date": "2024-09-25", "has_results": true, "last_update_posted_date": "2025-11-20", "last_synced_at": "2026-06-10T10:19:16.593Z", "location_count": 3, "location_summary": "Irvine, California • New York, New York • Arlington, Virginia", "locations": [ { "city": "Irvine", "state": "California" }, { "city": "New York", "state": "New York" }, { "city": "Arlington", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05954143" } ] }